Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tetrahydrocannabinol,Cannabidiol
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Data from three randomized, placebo-controlled trials of nabiximols (GWMS0106, GWSP0604, and SAVANT) conducted were analyzed to assess the relationship between measures of spasticity and muscle strength in lower extremities or walking speed.
Product Name : Nabiximols
Product Type : Controlled Substance
Upfront Cash : Inapplicable
November 13, 2020
Lead Product(s) : Tetrahydrocannabinol,Cannabidiol
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tetrahydrocannabinol,Cannabidiol
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Results from post-hoc analysis of phase 3 clinical study show nabiximols was well-tolerated and provided continued reductions in spasticity for individuals who remained on therapy.
Product Name : Nabiximols
Product Type : Controlled Substance
Upfront Cash : Inapplicable
October 09, 2020
Lead Product(s) : Tetrahydrocannabinol,Cannabidiol
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Epidiolex (cannabidiol), is a prescription, plant-derived cannabis-based medicine which is act CB receptor agonist, administered as an oral solution which contains highly purified cannabidiol (CBD), which is used for Lennox-Gastaut Syndrome and Dravet sy...
Product Name : Epidiolex
Product Type : Controlled Substance
Upfront Cash : Inapplicable
March 08, 2020
Lead Product(s) : Cannabidiol
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable